DIVI'S LABS: ELI LILLY'S ORAL GLP-1 DRUG RECEIVES POSITIVE EU REGULATORY OPINION 🟢

• European Medicines Agency's CHMP recommended approval of Eli Lilly's Foundayo (Orforglipron) on October 15, 2026. • Oral GLP-1 drug intended for Type 2 diabetes treatment and weight management. • Positive opinion is a major regulatory milestone; final European Commission approval is still pending. • Potential Positive for Divi's Labs: Commercialisation could increase API manufacturing opportunities if Divi's is part of Eli Lilly's supply chain. Impact: Potentially Positive 🟢 — However, the document does not confirm Divi's Labs as an Orforglipron supplier or quantify any revenue benefit.

← Back to feed